Search Results | Clinical Cancer Research | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Florence Atrafi, Oliver Boix, Vivek Subbiah, Jennifer R. Diamond, Sant P. Chawla, Anthony W. Tolcher, Patricia M. LoRusso, Joseph P. Eder, Martin Gutierrez, Kumar Sankhala, Prabhu Rajagopalan, Isabelle Genvresse, Simon Langer, Ron H.J. Mathijssen, Jaap Verweij, Ingmar Bruns, Martijn P. Lolkema

Clin Cancer Res (2022) 28 (13): 2969.

DOI: https://doi.org/10.1158/1078-0432.CCR-22-1792

Published: 01 July 2022

View article

Journal Articles

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

Clin Cancer Res (2021) 27 (23): 6366–6375.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4185

Published: 01 December 2021

View article

Includes: Supplementary data

Journal Articles

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

Clin Cancer Res (2021) 27 (2): 460–472.

DOI: https://doi.org/10.1158/1078-0432.CCR-20-1830

Published: 19 January 2021

View article

Includes: Supplementary data

Journal Articles

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

Clin Cancer Res (2019) 25 (22): 6709–6720.

DOI: https://doi.org/10.1158/1078-0432.CCR-19-0526

Published: 15 November 2019

View article

Includes: Supplementary data

Journal Articles

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Edward S. Kim, Karen Kelly, Luis G. Paz-Ares, Pilar Garrido, Shadia Jalal, Daruka Mahadevan, Martin Gutierrez, Mariano Provencio, Eric Schaefer, Monte Shaheen, Erica L. Johnston, P. Kellie Turner, Siva Rama Prasad Kambhampati, Richard Beckmann, Anwar Hossain, William J. John, Jonathan W. Goldman

Clin Cancer Res (2018) 24 (22): 5543–5551.

DOI: https://doi.org/10.1158/1078-0432.CCR-18-0651

Published: 15 November 2018

View article

Includes: Supplementary data

Journal Articles

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients

Yuebi Hu, Ryan S. Alden, Justin I. Odegaard, Stephen R. Fairclough, Ruthia Chen, Jennifer Heng, Nora Feeney, Rebecca J. Nagy, Jayshree Shah, Bryan Ulrich, Martin Gutierrez, Richard B. Lanman, Judy E. Garber, Cloud P. Paweletz, Geoffrey R. Oxnard

Clin Cancer Res (2017) 23 (23): 7351–7359.

DOI: https://doi.org/10.1158/1078-0432.CCR-17-1745

Published: 30 November 2017

View article

Includes: Supplementary data

Journal Articles

Development of a quantitative enzyme immunoassay for measurement of PAR as a pharmacodynamic biomarker of PARP activity

Clin Cancer Res (2006) 12 (19_Supplement): A5.

Published: 15 August 2014

View article

Journal Articles

A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Eva Szabo, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg, Giuseppe Giaccone

Clin Cancer Res (2012) 18 (8): 2344–2351.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-2425

Published: 16 April 2012

View article

Includes: Supplementary data

Journal Articles

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Arun Rajan, Ronan J. Kelly, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummar, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, Baskar Mannargudi, William D. Figg, Brett E. Houk, Michael Shnaidman, Nicoletta Brega, Giuseppe Giaccone

Clin Cancer Res (2011) 17 (21): 6831–6839.

DOI: https://doi.org/10.1158/1078-0432.CCR-11-0821

Published: 31 October 2011

View article

Includes: Supplementary data

Journal Articles

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

Ronan J. Kelly, Arun Rajan, Jeremy Force, Ariel Lopez-Chavez, Corrine Keen, Liang Cao, Yunkai Yu, Peter Choyke, Baris Turkbey, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, John J. Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone

Clin Cancer Res (2011) 17 (5): 1190–1199.

DOI: https://doi.org/10.1158/1078-0432.CCR-10-2331

Published: 01 March 2011

View article

Includes: Supplementary data

Journal Articles

Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy

Nilofer S. Azad, Jeanny B. Aragon-Ching, William L. Dahut, Martin Gutierrez, William D. Figg, Lokesh Jain, Seth M. Steinberg, Maria L. Turner, Elise C. Kohn, Heidi H. Kong

Clin Cancer Res (2009) 15 (4): 1411–1416.

DOI: https://doi.org/10.1158/1078-0432.CCR-08-1141

Published: 19 February 2009

View article

Journal Articles

Patient Perspectives on Phase 0 Clinical Trials

Martin Gutierrez, Deborah Collyar

Clin Cancer Res (2008) 14 (12): 3689–3691.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-4561

Published: 16 June 2008

View article

Journal Articles

Designing Phase 0 Cancer Clinical Trials

Anthony J. Murgo, Shivaani Kummar, Larry Rubinstein, Martin Gutierrez, Jerry Collins, Robert Kinders, Ralph E. Parchment, Jiuping Ji, Seth M. Steinberg, Sherry X. Yang, Melinda Hollingshead, Alice Chen, Lee Helman, Robert Wiltrout, Joseph E. Tomaszewski, James H. Doroshow

Clin Cancer Res (2008) 14 (12): 3675–3682.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-4560

Published: 16 June 2008

View article

Journal Articles

Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies

Shivaani Kummar, Martin Gutierrez, Erin R. Gardner, Erin Donovan, Kyunghwa Hwang, Eun Joo Chung, Min-Jung Lee, Kim Maynard, Mikhail Kalnitskiy, Alice Chen, Giovanni Melillo, Qin C. Ryan, Barbara Conley, William D. Figg, Jane B. Trepel, James Zwiebel, James H. Doroshow, Anthony J. Murgo

Clin Cancer Res (2007) 13 (18): 5411–5417.

DOI: https://doi.org/10.1158/1078-0432.CCR-07-0791

Published: 17 September 2007

View article

NARROW

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients

Development of a quantitative enzyme immunoassay for measurement of PAR as a pharmacodynamic biomarker of PARP activity

A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib

Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy

Patient Perspectives on Phase 0 Clinical Trials

Designing Phase 0 Cancer Clinical Trials

Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only